Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 11, 2023 06:00 ET | Source: Enterome

Enterome announces first patient dosed in Phase 2 trial with OncoMimics™ immunotherapy EO2040 in Colorectal Cancer with ctDNA-defined Minimal Residual Disease

First clinical trial of an OncoMimics™ immunotherapy to use liquid biopsy monitoring to measure ctDNA clearance as an indicator of treatment efficacy EO2040 is Enterome’s fourth OncoMimics™...
June 30, 2023 06:00 ET | Source: Enterome

Enterome announces first patient dosed in a Phase 1/2 trial with third OncoMimics™ immunotherapy, EO4010, in Metastatic Colorectal Cancer

EO4010 uniquely mimics five distinct tumor-associated antigens designed to provide multi-targeted, broad tumor coverage, maximizing tumor killing and preventing immune escape Paris, France – June 30,...
June 14, 2023 06:00 ET | Source: Enterome

Enterome's new OncoMimics™ immunotherapy, EO2463, demonstrates early efficacy and favorable safety in Phase 1/2 trial for indolent non-Hodgkin lymphoma

EO2463 uniquely targets four distinct B cell markers to maximize tumor killing and prevent immune escape, generating fast, strong and durable CD8+ T cell activation against malignant B cells ...
May 31, 2023 06:00 ET | Source: Enterome

Enterome announces sustained positive clinical outcomes with EO2401, its lead OncoMimics™ immunotherapy, in combination therapy in Glioblastoma at ASCO

Updated clinical data highlight promising efficacy and sustained CD8+ T cell expansion Early data from final cohort could provide validation of the EO2401 + nivolumab + bevacizumab combination...
May 09, 2023 06:00 ET | Source: Enterome

Enterome forms Scientific Advisory Board and Medical Advisory Group as it advances its OncoMimics™ immunotherapy pipeline for solid and liquid tumors

SAB and MAG comprise global key opinion leaders in translational tumor immunology and immunotherapy Paris, France – May 9, 2023 Enterome, a clinical-stage company developing first-in-class...
March 10, 2023 07:00 ET | Source: Enterome

Enterome's Management to Attend Upcoming Meetings

Paris, France – March 10, 2023 Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for cancer and inflammatory diseases based on its unique Mimicry platform, today...

keyboard_arrow_left Previous Page